A detailed history of Vanguard Group Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Vanguard Group Inc holds 20,161,180 shares of ALKS stock, worth $487 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,161,180
Previous 20,955,454 3.79%
Holding current value
$487 Million
Previous $581 Million 6.11%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$26.4 - $32.56 $21 Million - $25.9 Million
-794,274 Reduced 3.79%
20,161,180 $546 Million
Q4 2023

Feb 14, 2024

BUY
$23.37 - $28.68 $53.5 Million - $65.6 Million
2,288,185 Added 12.26%
20,955,454 $581 Million
Q3 2023

Nov 14, 2023

BUY
$27.17 - $31.97 $1.98 Million - $2.33 Million
72,797 Added 0.39%
18,667,269 $523 Million
Q2 2023

Aug 14, 2023

SELL
$28.34 - $33.63 $387,407 - $459,722
-13,670 Reduced 0.07%
18,594,472 $582 Million
Q1 2023

May 15, 2023

BUY
$25.31 - $29.02 $1.75 Million - $2 Million
69,064 Added 0.37%
18,608,142 $525 Million
Q4 2022

Feb 10, 2023

BUY
$21.94 - $26.24 $9.46 Million - $11.3 Million
431,176 Added 2.38%
18,539,078 $484 Million
Q3 2022

Nov 14, 2022

BUY
$22.0 - $31.87 $18.2 Million - $26.4 Million
828,769 Added 4.8%
18,107,902 $404 Million
Q2 2022

Aug 12, 2022

BUY
$26.4 - $30.54 $12.8 Million - $14.8 Million
486,023 Added 2.89%
17,279,133 $515 Million
Q1 2022

May 13, 2022

SELL
$23.07 - $27.99 $2.27 Million - $2.76 Million
-98,600 Reduced 0.58%
16,793,110 $442 Million
Q4 2021

Feb 14, 2022

BUY
$21.47 - $32.08 $1.14 Million - $1.7 Million
52,885 Added 0.31%
16,891,710 $393 Million
Q3 2021

Nov 12, 2021

BUY
$23.37 - $32.13 $5.57 Million - $7.66 Million
238,336 Added 1.44%
16,838,825 $519 Million
Q2 2021

Aug 13, 2021

BUY
$18.78 - $25.15 $312 Million - $418 Million
16,600,489 New
16,600,489 $407 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $3.97B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.